NeoGenomics Inc (NEO)
15.30
+0.58
(+3.94%)
USD |
NASDAQ |
May 03, 16:00
15.30
0.00 (0.00%)
After-Hours: 20:00
NeoGenomics Enterprise Value: 2.108B for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 2.108B |
| May 02, 2024 | 2.034B |
| May 01, 2024 | 1.937B |
| April 30, 2024 | 1.932B |
| April 29, 2024 | 2.098B |
| April 26, 2024 | 1.960B |
| April 25, 2024 | 1.919B |
| April 24, 2024 | 1.942B |
| April 23, 2024 | 1.959B |
| April 22, 2024 | 1.864B |
| April 19, 2024 | 1.878B |
| April 18, 2024 | 1.909B |
| April 17, 2024 | 1.897B |
| April 16, 2024 | 1.919B |
| April 15, 2024 | 1.906B |
| April 12, 2024 | 1.950B |
| April 11, 2024 | 2.004B |
| April 10, 2024 | 1.997B |
| April 09, 2024 | 2.094B |
| April 08, 2024 | 2.046B |
| April 05, 2024 | 2.055B |
| April 04, 2024 | 2.039B |
| April 03, 2024 | 2.049B |
| April 02, 2024 | 2.041B |
| April 01, 2024 | 2.115B |
| Date | Value |
|---|---|
| March 31, 2024 | 2.157B |
| March 28, 2024 | 2.130B |
| March 27, 2024 | 2.064B |
| March 26, 2024 | 2.058B |
| March 25, 2024 | 2.007B |
| March 22, 2024 | 2.064B |
| March 21, 2024 | 2.093B |
| March 20, 2024 | 2.106B |
| March 19, 2024 | 2.001B |
| March 18, 2024 | 1.980B |
| March 15, 2024 | 1.998B |
| March 14, 2024 | 2.003B |
| March 13, 2024 | 2.097B |
| March 12, 2024 | 2.084B |
| March 11, 2024 | 2.156B |
| March 08, 2024 | 2.121B |
| March 07, 2024 | 2.160B |
| March 06, 2024 | 2.137B |
| March 05, 2024 | 2.134B |
| March 04, 2024 | 2.174B |
| March 01, 2024 | 2.161B |
| February 29, 2024 | 2.114B |
| February 28, 2024 | 2.109B |
| February 27, 2024 | 2.181B |
| February 26, 2024 | 2.199B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
907.39M
Minimum
Oct 21 2022
6.864B
Maximum
Feb 12 2021
3.009B
Average
2.468B
Median
Enterprise Value Benchmarks
| Teladoc Health Inc | 2.609B |
| Abbott Laboratories | 191.38B |
| Halozyme Therapeutics Inc | 6.225B |
| Verastem Inc | 178.81M |
| Ocugen Inc | 305.59M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -27.06M |
| Revenue (Quarterly) | 156.24M |
| Total Expenses (Quarterly) | 184.41M |
| EPS Diluted (Quarterly) | -0.21 |
| Gross Profit Margin (Quarterly) | 41.90% |
| Profit Margin (Quarterly) | -17.32% |
| Earnings Yield | -4.31% |
| Normalized Earnings Yield | -3.892 |